We are live on ! Find out more
MTCR

Metacrine, Inc. Common Stock

Delisted

MTCR was delisted on the 8th of February, 2023.

42 hedge funds and large institutions have $47.3M invested in Metacrine, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less funds holding

Funds holding: 4742 (-5)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

40% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 15

42% less capital invested

Capital invested by funds: $82.1M → $47.3M (-$34.7M)

Holders
42
Holders Change
-5
Holders Change %
-10.64%
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
9
Reduced
15
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
-$3K -555 Closed
Legal & General Group
52
Legal & General Group
United Kingdom
-$3K -527 Closed
Citigroup
53
Citigroup
New York
-$1.89K -456 -84%
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
-$1K -233 Closed

MTCR Hedge Fund Activity: Q2 2021 in Review

42 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q2 2021, worth a combined $47.3M — down 42% from $82.1M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of MTCR and 8 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 9 added.

The largest buyer was Prosight Management, adding an estimated $2.33M. The largest seller was VR Adviser, exiting entirely with an estimated $4.22M sold.

  • 42 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q2 2021, down from 47 in Q1 2021.
  • Funds reported $47.3M of Metacrine, Inc. Common Stock stock for Q2 2021, down 42% quarter-over-quarter.
  • 8 funds opened new Metacrine, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of -5 holders.
  • The largest Metacrine, Inc. Common Stock buyer in Q2 2021 was Prosight Management, an estimated $2.33M added.
  • The largest Metacrine, Inc. Common Stock seller in Q2 2021 was VR Adviser, an estimated $4.22M sold.

Based on aggregated 13F filings for Q2 2021.